Company name: Endomag
Website: www.endomag.com
At Endomag, we believe everyone deserves a better standard of cancer care - that's why we design our cancer localisation technologies with both the clinician and patient in mind. Many leading hospitals across the world use our unique solutions to help breast cancer patients avoid surgery when it isn't needed, and experience better outcomes when it is.
Our Magseed® marker is a tiny, non-radioactive seed, ideal for accurately marking tumours and lymph nodes, while the Magtrace® lymphatic tracer is the world's first, long-lasting, non-radioactive dual tracer for lymphatic mapping. Paired with the Sentimag® localisation platform, they have now been widely proven across over 200 clinical studies, featuring more than 20,000 patients.
At this year's ORBS meeting, we're stepping things up... drop by our booth or join us at our workshop to try out the NEW Sentimag® Gen 3 platform. Find out how it could help you deliver more precise, and less invasive breast cancer treatment. Are you ready to join the magnetic revolution?
To find out more, visit www.endomag.com